A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103)

A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103)

By: Alexandra de Leon Date: July 8th, 2020

Stay Connected

Other Publications

More events you may be interested in.

+ Development and Evaluation of an Online Toolkit for Managers of 9-1-1 Emergency Communications Centers to Reduce Occupational Stress.
+ Pain relief after topical capsaicin: does it result from nociceptor degeneration or regeneration?
+ Proceedings from the 2022 Consensus Conference to Implement Optimal Venous Thromboembolism Prophylaxis in Trauma.
+ Testing the Impact of Protocolized Care of Patients With Severe Traumatic Brain Injury Without Intracranial Pressure Monitoring: The Imaging and Clinical Examination Protocol.
+ Rural-Urban Variation in the Association of Adolescent Violence and Handgun Carrying in the United States, 2002-2019.

Custom Link To Another Page Goes Here